Wayne Winegarden
Commentary
Trump’s Drug Importation Policy Is Folly, Just Ask Canadians
The Trump Administration’s Department of Health and Human Services (HHS) has officially proposed legalizing the importation of drugs from Canada (e.g. the Safe Importation Action Plan). Canadians’ reactions provide an important perspective demonstrating why drug importation will harm the U.S. Despite assurances from Prime Minister Justin Trudeau, Canadians are worried ...
Commentary
Americans Support Paying for Miracle Cures
Without pro-market payment reforms, cutting edge medical treatments known as gene therapies run the risk of becoming the dance that no one attends. Gene therapies are not medicines, instead, they are akin to an organ transplant. These procedures typically use re-engineered viruses to repair, replace, or shut off malfunctioning genes ...
Commentary
Wayne Winegarden in Forbes: Inflation Caps Are Price Controls By Another Name
From the time we were toddlers, it has always been tempting to bang the square peg into the round hole. After all, there is always that one square peg that seems like it should just about fit into that round hole, and it would feel so satisfying if it did. ...
Health Care
ISSUE BRIEF: Increased Use of Biosimilars Could Bring Billions in Savings for Patients, Providers, Taxpayers
Biosimilars have the potential to realize billions in savings for the health care system if reforms are enacted to incent their market share to grow, according to a new issue brief issued today by the Center for Medical Economics and Innovation at the California-based, free-market think tank, the Pacific Research ...
Commentary
Trump’s Healthcare Contradictions Threaten Beneficial Reforms
The Trump Administration is proposing a litany of contradictory healthcare reforms. Some reforms will empower patients, improve incentives, and strengthen the healthcare system. Others empower bureaucrats, worsen incentives, and will restrict patients’ access to needed healthcare treatments. A better outcome will only emerge if the Administration jettisons the ill-advised proposals ...
Commentary
Flawed WHO Study Could Jeopardize Patients’ Access to Cancer Medicines
Determining whether the prices for medicines are appropriate or not is critically important, which is why studies that attempt to answer this question must stand up to scrutiny. Studies that undervalue medicines jeopardize the development of future cures, while studies that overvalue medicines justify the imposition of excessive health care ...
Business & Economics
Are ESG Funds A Good, Long-Term Investment?
One of the hottest investment trends promises to do well while by doing good. This investment trend is called environmental, social, and governance investing, or ESG funds. Not all ESG funds have similar investment strategies. Some ESG funds actively invest in companies that meet specific environmental or social criteria. These ...
Commentary
Don’t Legislate Away Biopharmaceutical Innovation
The U.S. economy thrives on innovation. According to the U.S. Patent and Trademark Office, industries that intensively rely on intellectual property (IP) protections, which includes the biopharmaceutical industry, account for nearly 40 percent of the U.S. economy and are responsible for an outsized share of our overall economic growth. Beyond the ...
Blog
“HELP-ing” to Make Health Care More Affordable
The Senate Health, Education, Labor & Pensions (HELP) Committee has just released a bi-partisan bill authored by Senators Lamar Alexander (R-TN) and Patty Murray (D-WA) that would make health care more affordable and more transparent for patients. These reforms are not grandiose fantasies that are destined to fail, such as ...
Commentary
Differentiating Health Care Costs from Health Care Value
The wrong model, no matter how hard you work it, will never provide the right answer. When it comes to how we pay for health care, the U.S. is using the wrong model. What’s worse, these financing inadequacies could threaten the viability of new therapies that will bring hope to ...
Trump’s Drug Importation Policy Is Folly, Just Ask Canadians
The Trump Administration’s Department of Health and Human Services (HHS) has officially proposed legalizing the importation of drugs from Canada (e.g. the Safe Importation Action Plan). Canadians’ reactions provide an important perspective demonstrating why drug importation will harm the U.S. Despite assurances from Prime Minister Justin Trudeau, Canadians are worried ...
Americans Support Paying for Miracle Cures
Without pro-market payment reforms, cutting edge medical treatments known as gene therapies run the risk of becoming the dance that no one attends. Gene therapies are not medicines, instead, they are akin to an organ transplant. These procedures typically use re-engineered viruses to repair, replace, or shut off malfunctioning genes ...
Wayne Winegarden in Forbes: Inflation Caps Are Price Controls By Another Name
From the time we were toddlers, it has always been tempting to bang the square peg into the round hole. After all, there is always that one square peg that seems like it should just about fit into that round hole, and it would feel so satisfying if it did. ...
ISSUE BRIEF: Increased Use of Biosimilars Could Bring Billions in Savings for Patients, Providers, Taxpayers
Biosimilars have the potential to realize billions in savings for the health care system if reforms are enacted to incent their market share to grow, according to a new issue brief issued today by the Center for Medical Economics and Innovation at the California-based, free-market think tank, the Pacific Research ...
Trump’s Healthcare Contradictions Threaten Beneficial Reforms
The Trump Administration is proposing a litany of contradictory healthcare reforms. Some reforms will empower patients, improve incentives, and strengthen the healthcare system. Others empower bureaucrats, worsen incentives, and will restrict patients’ access to needed healthcare treatments. A better outcome will only emerge if the Administration jettisons the ill-advised proposals ...
Flawed WHO Study Could Jeopardize Patients’ Access to Cancer Medicines
Determining whether the prices for medicines are appropriate or not is critically important, which is why studies that attempt to answer this question must stand up to scrutiny. Studies that undervalue medicines jeopardize the development of future cures, while studies that overvalue medicines justify the imposition of excessive health care ...
Are ESG Funds A Good, Long-Term Investment?
One of the hottest investment trends promises to do well while by doing good. This investment trend is called environmental, social, and governance investing, or ESG funds. Not all ESG funds have similar investment strategies. Some ESG funds actively invest in companies that meet specific environmental or social criteria. These ...
Don’t Legislate Away Biopharmaceutical Innovation
The U.S. economy thrives on innovation. According to the U.S. Patent and Trademark Office, industries that intensively rely on intellectual property (IP) protections, which includes the biopharmaceutical industry, account for nearly 40 percent of the U.S. economy and are responsible for an outsized share of our overall economic growth. Beyond the ...
“HELP-ing” to Make Health Care More Affordable
The Senate Health, Education, Labor & Pensions (HELP) Committee has just released a bi-partisan bill authored by Senators Lamar Alexander (R-TN) and Patty Murray (D-WA) that would make health care more affordable and more transparent for patients. These reforms are not grandiose fantasies that are destined to fail, such as ...
Differentiating Health Care Costs from Health Care Value
The wrong model, no matter how hard you work it, will never provide the right answer. When it comes to how we pay for health care, the U.S. is using the wrong model. What’s worse, these financing inadequacies could threaten the viability of new therapies that will bring hope to ...
